What is Type 2 Inflammation?
Type 2 inflammation is an overactive immune response involving specific cells (Th2 cells), cytokines (IL-4, IL-5, IL-13), IgE antibodies, and eosinophils that drives many chronic allergic and inflammatory conditions. It's the underlying mechanism connecting conditions across the skin, lungs, gut, and sinuses.
Understanding it can explain why people with one condition so often develop others and why targeted biologic treatments are changing the landscape of care.
If you have asthma, eczema, nasal polyps, or more than one of these, Type 2 inflammation may be the common thread. This guide explains what it is, why conditions cluster, and what it means for treatment.
6 episodes · Patients, families & clinicians
Type 2 inflammation
Learn about type 2 inflammation in 3 MODULES
Quick look
MODULE 1
What is Type 2 inflammation?
New to Type 2 inflammation? This episode breaks down the basics of the immune system, what Th2 cells, cytokines, and eosinophils actually do, how chronic inflammation differs from a normal immune response, and why understanding this pathway matters for treatment.
Start here!
Ep. 101
What Is Type 2 Inflammation?
Dr. Gupta uses an analogy to explain how Th2 cells, cytokines (IL-4, IL-5, IL-13), and IgE antibodies interact and how blood tests can identify whether Type 2 inflammation is driving your symptoms.
Resources
Type 2 Inflammation Overview, Allergy & Asthma Network
Biologics: What They Are, How They Work & Who Might Benefit, Allergy & Asthma Network Webinar
MODULE 2
How Type 2 inflammation connects conditions
Type 2 inflammation is a shared immune pathway that drives conditions across multiple organ systems. Conditions like asthma, eczema, nasal polyps, EoE, and food allergies often co-occur in the same patient, not by coincidence, but because they share an underlying inflammatory pathway.
Recognizing that connection can be a game-changer for diagnosis and treatment: instead of managing each condition separately, targeting the root inflammation may reduce them all. In children, this clustering can progress over time in a pattern called the atopic march, and early intervention may be able to slow or stop it.
Ep. 102
Comorbidities of Type 2 Inflammation: Connecting the Dots
Dr. Blaiss joins Dr. Gupta and Kortney to explore how CRSwNP, rhinitis, asthma, eczema, EoE, and food allergies can all share the same inflammatory pathway and why recognizing this overlap is a game-changer for diagnosis and treatment.
Resources
Type 2 Inflammation in Asthma, Allergy & Asthma Network
Aspirin-Exacerbated Respiratory Disease (AERD) & Type 2 Inflammation, Allergy & Asthma Network Webinar
Eosinophilic Esophagitis (EoE), Allergy & Asthma Network
Chronic Rhinosinusitis with Nasal Polyps, Allergy & Asthma Network
Ep. 103
Pediatric Type 2 Inflammation: Can We Slow or Stop Allergic Conditions in Children?
Dr. Priya Bansal joins to explore the atopic march, when to see an allergist, and whether allergy shots, OIT, SLIT, or biologics can alter the course of disease in children with multiple allergic conditions.
MODULE 3
Dive deeper!
Achieving control
Control doesn't mean cure. It means fewer, milder flare-ups and the freedom to live more comfortably. This module covers what control looks like across Type 2 conditions, how to recognize when your treatment isn't working, and what Type 2 inflammation-targeted treatment looks like in practice, including a research deep dive into tezepelumab, a biologic that blocks TSLP upstream of the entire T2 cascade.
Ep. 104
Achieving Control in Type 2 Inflammation
Dr. Gupta and Kortney, who manages asthma and eczema with biologics, discuss what control means, warning signs of uncontrolled disease, the role of biologics and trigger avoidance, and when to seek a second opinion.
Resources
Achieving Control in Type 2 Inflammation, Allergy & Asthma Network
The Itch Review: Type 2 inflammation-targeted treatment in practice
These Itch Review episodes show what treating Type 2 inflammation at the source looks like in the real world. CRSwNP is one of the clearest examples of T2 driving a condition, and tezepelumab, which targets TSLP upstream of the entire pathway, shows how far T2-targeted therapy has come.
Ep. 133
What Is Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)?
How Type 2 inflammation directly drives polyp formation in the sinuses, and why CRSwNP often appears alongside asthma and eczema in the same patient.
Ep. 109
Tezepelumab & Nasal Polyps: Inside the WAYPOINT Phase III Trial
In the inaugural Itch Review episode, Dr. Gupta, Kortney, and Dr. Blaiss break down the WAYPOINT trial and what blocking TSLP means for patients who haven't responded to other biologics.
Resources
Chronic Rhinosinusitis with Nasal Polyps, Allergy & Asthma Network
Nasal Polyps, Allergy & Asthma Network
Dive even deeper
Biologics & medications
Ready to understand the specific medications used to treat T2 conditions? Our medications guide covers what biologics are, how they work, and what to expect when starting one.
Medications & biologics guide →